Kymera Therapeutics Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $105M+123.1% YoYTTM through 30 Jun 2026
Net Income -$299.6MTTM through 30 Jun 2026
Free Cash Flow -$238MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| EBITDA Margin | -325.7% |
| Operating Margin | -244.8% |
| Net Margin | -285.3% |
Returns
-20.5%ROE
-18.9%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio11.95x
Net Debt-$1.5Bnet cash position
Cash & Equivalents$124.5M
Quality Metrics
Altman Z-Score43.06
Piotroski F-Score2 / 9
FCF Margin-226.6%
Rule of 40-225.5
Earnings-Beat Rate25.0%
Multi-Year Trend
RevenueFY2025: $39.2M
Diluted EPS-$3.25TTMFY2025: $-3.69
Dividend
No dividend
Capital Allocation
Capex Intensity1.1%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Collaboration Revenues | $34.4M | +55.7% | View detailsFuture revenues will continue to be driven by milestone achievements under existing collaborations with Gilead and Sanofi. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.